Tryton Medical’s Side-Branch Stent Demonstrates Unparalleled Ease-of-Use to Definitively Treat Wide Variety of Extremely Challenging Bifurcated Lesions at EuroPCR 2007

Dateline City: NEWTON, Mass. Thousands of Leading Interventional Cardiologists Witness New Paradigm Shift in Cardiology Procedures NEWTON, Mass.–(BUSINESS WIRE)–Tryton Medical, Inc., announced it successfully treated extremely challenging cases at EuroPCR 2007 in Barcelona, Spain to demonstrate how the firm’s Side-Branch Stent will ultimately reshape the treatment of bifurcated lesions. EuroPCR provided an important informational venue that enabled thousands of interventional …

Tryton Medical’s Side-Branch Stent™ Demonstrates Unparalleled Ease-of-Use and Definitive Treatment of Bifurcation Lesions at TCT Asia 2007 and at the American College of Cardiology’s Innovation and Intervention (i2) Summit in New Orleans

Dateline City: NEWTON, Mass. Interventional Cardiologists Treat Complex Lesions Within 10 Minutes, With Superb Angiographic Results NEWTON, Mass.–(BUSINESS WIRE)–Tryton Medical, Inc. has marked new milestones in stent technology by demonstrating on a global scale how the firm’s Side-Branch Stent offers unparalleled ease-of-use and the best option to safely and definitively treat bifurcation lesions. Tryton transmitted a live satellite feed of …

Tryton Medical, Inc. Broadcasts Successful Live Case Using Company’s Side-Branch Stent™ to Definitively Treat Bifurcation Lesions in Front of 1,000 Cardiologists at JIM 2007 Conference in Rome

Dateline City: NEWTON, Mass. NEWTON, Mass.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced that it transmitted a live satellite feed of a clinical case, which was performed at the Helios Heart Center in Siegburg Germany, to an audience of over 1,000 interventional cardiologists at the Joint Interventional Meeting (JIM 2007) in Rome. The …

Tryton Medical Completes Enrollment Phase of First-in-Man Study– 30 Patients With Coronary Bifurcation Lesions Treated Using Company’s Side-Branch Stent™

Dateline City: NEWTON, Mass. NEWTON, Mass.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced it completed the enrollment phase of the Tryton First-in-Man (FIM) Study. The multi-center clinical trial evaluated the safety of Tryton’s Side-Branch Stent in the treatment of coronary bifurcation lesions. The Study was performed at the: HELIOS Heart Center/Siegburg, Germany (Prof. …